Johnson & Johnson Secures Exclusive Option for Sail Bio's In Vivo CAR-T Candidate, SAIL-0839
Johnson & Johnson (J&J) has entered into a collaboration and exclusive option agreement with Sail Biomedicines, a Flagship Pioneering company, to co-develop and potentially acquire the rights to SAIL-0839, a preclinical-stage in vivo CAR-T therapy. The agreement includes an upfront payment of $785 million, including a $465 million equity investment in Sail. J&J will also provide up to $140 million in milestone payments and has the option to acquire Sail for an additional $2.58 billion. This significant investment reflects J&J's commitment to overcoming the complexities of traditional cell therapies and establishing a leading position in the next-generation autoimmune disease market.
SAIL-0839, the core of this collaboration, utilizes Sail Biomedicines' proprietary 'endless RNA (eRNA™)' technology and programmable nanoparticle delivery platform. This therapy is designed to directly reprogram CD4+ and CD8+ T cells in vivo to target the CD19 protein found on B cells. Traditional ex vivo CAR-T therapies involve extracting T cells from a patient's blood, genetically modifying them, and then re-infusing them, a process that takes 3-4 weeks and is associated with high costs and potential side effects. In contrast, in vivo technology aims to induce an immune reset directly within the patient's body, eliminating the need for complex cell culture processes and pre-conditioning chemotherapy. This approach offers the potential for a more readily available and accessible treatment option, paving the way for the widespread adoption of cell therapies.
The global autoimmune disease market is projected to reach $250 billion by 2030, with the systemic lupus erythematosus (SLE) market expected to reach $5.75 billion by 2030. J&J has already achieved success in the ex vivo CAR-T space with Carvykti (ciltacabtagene autoleucel), co-developed with Legend Biotech, and is now seeking to expand its dominance into the autoimmune disease area. With competitors such as Cabaletta Bio (CABA-201) and Kyverna Therapeutics (KYV-101) having their ex vivo pipelines in Phase 1/2 trials, J&J aims to disrupt the market with its in vivo technology.
This deal highlights the technological value of Sail Biomedicines, which was formed through the merger of Senda Biosciences and Laronde in 2023, and the incubation capabilities of Flagship Pioneering. With Eli Lilly's acquisition of Kelonia Therapeutics and Bristol Myers Squibb's collaboration with Orbital Therapeutics, the competition for in vivo cell therapies is intensifying. With Gilead Sciences and AstraZeneca also joining the fray through partnerships with Interius and Cellectis, respectively, the value of biotech companies with next-generation platform technologies is expected to continue to rise.
This deal involves an upfront payment of $785 million, milestone payments of $140 million, and a future acquisition option of $2.58 billion for SAIL-0839, a preclinical in vivo CAR-T therapy. From an investor's perspective, it confirms the commercial value of next-generation platform technologies that can replace the existing high-cost ex vivo approach in the autoimmune disease market, which is expected to grow to $250 billion by 2030. For researchers, it presents a new technological standard by combining Sail's eRNA™ platform and nanoparticle technology to directly reprogram CD4+/CD8+ T cells in vivo and target CD19. In the short term, it will inevitably lead to a reshuffling of the competitive landscape with existing ex vivo pipelines in Phase 1/2 trials, such as Kyverna's KYV-101 and Cabaletta's CABA-201. In the medium to long term, J&J is expected to gain a strong leading position in the in vivo cell therapy development competition with companies such as Lilly (Kelonia acquisition), BMS (Orbital collaboration), and AstraZeneca (Cellectis collaboration).
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/johnson-johnson-sail-option-acquire-in-vivo-car-t/826589/